丁香园肿瘤资讯翻译.docx

粗译1、Overall survival was improved in metastatic pancreatic cancer patients through an innovative immunotherapy strategy in a multicenter study reported at the 2014 Gastrointestinal CancersSymposium.据2014胃肠肿瘤学峰会上发布的一项多中心研究显示，转移性胰腺癌患者通过全新的免疫治疗策略可提高总生存时间。2、“This is the first time a randomized study has shown that immunotherapy is effective in pancreatic cancer,” said Dung T. Le, MD, Assistant Professor of Medicine at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore. “This is just a first step, and we believe we’ll be able to take this approach further.”“这是首次有随机对照试验显示免疫治疗在胰腺癌中有效”，来自巴尔的摩的约翰霍普金斯大学西德尼·基梅尔肿瘤综合中心（Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center）的内科学助理教授、医学博士Dung T. Le如是说。“这仅仅是第一步，我们相信我们可以在这条道路上走得更远。”How the Treatment Works治疗如何发挥作用3、The novel treatment, which may be better tolerated than standard chemotherapy, involves two different anticancer vaccines: GVAX Pancreas followed by CRS-207. GVAX is composed of pancreatic cancer cells that have been genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates the immune system. GVAX is given with low-dose cyclophosphamide to inhibit regulatory T cells and boost the vaccine’s efficacy. The second vaccine, CRS-207, is live-attenuated Listeria monocytogenes (Lm), which has been genetically modified to be safe for human use while retaining its ability to stimulate an immune response against the protein mesothelin on pancreatic tumor cells.这项比标准化疗更容易耐受的创新性治疗涉及两种不同的抗肿瘤疫苗：GVAX Pancreas和CRS-207。GVAX由基因修饰过的胰腺癌细胞组成，后者可以分泌粒细胞-巨噬细胞集落刺激因子（GM-CSF）激活免疫系统。低剂量的环磷酰胺和GVAX一同应用，旨在抑制调节性T细胞（?regulatory T cells）并增加疫苗的功效。第二种疫苗CRS-207，是一种减毒产单核李斯特菌（live-attenuatedListeria monocytogenes，Lm）。该菌经基因修饰后对人体安全的同时，保留了其刺激免疫反应对抗胰腺癌细胞中的间皮素的能力。4、The combination essentially trains the body to recognize and attack pancreatic tumors. In mouse tumor models, Lm/GVAX vaccines are synergistic, and in a phase I study of CRS-207, patients with pancreatic ductal ad